40 completed, 17 recruiting, 13 unknown, 10 active not recruiting. 96 Phase 2, 18 Phase 1, 4 Phase 3.
Follow Thyroid Cancer: new trials by email Literature Review of Thyroid Cancer trials Research Report on Thyroid Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid Cancer Dabrafenib, Trametinib, Pembrolizumab - Anaplastic Thyroid Carcinoma, Thyroid Cancer | Phase 2 | Not yet recruiting | Washington University School of Medicine | 12 | 2026-12-31 | 2026-10-21 |
| 177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer 68Ga-DOTA-TATE PET Scan, Amino acid infusions, 177Lu-DOTA-EB-TATE - Thyroid Cancer | Phase 1 / Phase 2 | Not yet recruiting | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 18 | 2026-11-18 | 2026-11-13 |
| MRG003 Added to Ongoing Treatment After Progression in EGFR-Positive Advanced Thyroid Cancer Becotatug Vedotin (MRG003), Lenvatinib, Anti-PD-1 Inhibitor (Continuation of Prior Treatment) - Thyroid Cancer, Tumor | Phase 2 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 39 | 2026-09-20 | 2026-10-14 |
| Selective Coverage Versus Comprehensive Coverage Radiotherapy in Poorly Differentiated and Anaplastic Thyroid Cancer Selective coverage radiotherapy, comprehensive coverage radiotherapy - Thyroid Cancer | Phase 2 | Recruiting | Fudan University | 72 | 2026-08-12 | 2026-08-20 |
| FAPI PET Imaging - An Exploratory Study [18F]FAPI-74 PET/CT - Thyroid Pathology, Head and Neck Cancer (H&N) | Phase 1 / Phase 2 | Not yet recruiting | Martin Huellner | 770 | 2026-08-01 | 2026-07-15 |
| Anlotinib and Benmelstobart in DTC Anlotinib and Benmelstobart - Thyroid Cancer | Phase 2 | Not yet recruiting | Fudan University | 23 | 2026-04-01 | 2026-02-27 |
| XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation XP-102, Trametinib - Cancer, BRAF V600 Mutation | Phase 1 / Phase 2 | Not yet recruiting | Xynomic Pharmaceuticals, Inc. | 221 | 2025-12-31 | 2025-04-10 |
| Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer Iodine-124, Positron Emission Tomography (PET)/Computerized tomography (CT) - Thyroid Cancer | Phase 2 | Recruiting | Thomas Hope | 62 | 2025-12-04 | 2026-06-18 |
| Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC) Lenvatinib - Thyroid Cancer, Cancer of the Thyroid | Phase 2 | Recruiting | Washington University School of Medicine | 34 | 2025-10-14 | 2026-03-17 |
| Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery Zanzalintinib - Neoadjuvant Treatment, Thyroid Cancer | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 45 | 2025-07-22 | 2026-11-05 |
| MRG003 and Pucotenlimab to Treat Locally Advanced or Metastatic ATC/PDTC MRG003 in combination with pucotenlimab - Thyroid Cancer | Phase 2 | Recruiting | Fudan University | 60 | 2025-04-21 | 2025-11-19 |
| Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC) Sacituzumab govitecan - Salivary Gland Cancer, Thyroid Cancer | Phase 2 | Recruiting | National University Hospital, Singapore | 32 | 2025-04-15 | 2025-07-25 |
| Oral Mecobalamin for TKI-Associated Hand-Foot Syndrome in Advanced Thyroid Cancer Mecobalamin, Urea Ointment - Thyroid Cancer, Hand-foot Syndrome | Phase 2 | Completed | Li Zhihui | 100 | 2025-04-12 | 2026-11-03 |
| Trop2-targeted immunoPET Imaging of Solid Tumors [68Ga]Ga-NOTA-T4, [68Ga]Ga-NOTA-RT4, [18F]F-RESCA-T4 - Solid Tumor, Solid Carcinoma | Phase 2 / Phase 3 | Recruiting | RenJi Hospital | 400 | 2024-12-23 | 2026-05-29 |
| Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer Cyclophosphamide+Pemetrexed+5-Fluorouracil, Cyclophosphamide+Doxorubicin+5-Fluorouracil, Vindesine + Cisplatin - Locally Advanced Thyroid Gland Carcinoma, Thyroid Cancer | Phase 2 | Not yet recruiting | West China Hospital | 20 | 2024-12-01 | 2024-12-03 |
| Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor Carbon Nanoparticle-Loaded Iron [CNSI-Fe], Carbon Nanoparticle-Loaded Iron - Tumor, Solid, Lung Cancer | Phase 1 / Phase 2 | Recruiting | Sichuan Enray Pharmaceutical Sciences Company | 54 | 2024-11-12 | 2026-02-25 |
| Donafenib Combined With Anti-PD-1 Antibody for Neoadjuvant Therapy in Locally Advanced Thyroid Cancer Donafeib with Sintilimab - Thyroid Cancer | Phase 2 | Recruiting | Yu Wang | 14 | 2024-07-24 | 2025-01-22 |
| Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors MDX2001 - Biliary Tract Cancer, Breast Cancer | Phase 1 / Phase 2 | Recruiting | ModeX Therapeutics, An OPKO Health Company | 330 | 2024-06-12 | 2026-10-15 |
| Famitinib in Combination With Adebrelimab for the Treatment of Advanced Thyroid Cancer 20 mg Famitinib & 1200 mg Adebrelimab - Thyroid Cancer | Phase 2 | Unknown | Ruijin Hospital | 67 | 2023-12-01 | 2023-11-28 |
| A Study of Avutometinib and Defactinib in People With Thyroid Cancer Avutometinib, Defactinib - Thyroid Cancer | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2023-08-16 | 2026-10-15 |
Showing 20 of 96. Sign in to see all of them.
Thyroid Neoplasms (96) · Stomach Neoplasms (9) · Breast Neoplasms (8) · Carcinoma, Non-Small-Cell Lung (8) · Thyroid Carcinoma, Anaplastic (8) · Colonic Neoplasms (7) · Head and Neck Neoplasms (7) · Lung Neoplasms (7) · Neoplasm Metastasis (7) · Neoplasms (7) · Prostatic Neoplasms (7) · Ovarian Neoplasms (6) · Pancreatic Neoplasms (6) · Thyroid Cancer, Papillary (6) · Uterine Cervical Neoplasms (6)
Endocrine System Diseases (96) · Neoplasms by Site (96) · Endocrine Gland Neoplasms (95) · Thyroid Diseases (92) · Head and Neck Neoplasms (89) · Neoplasms (89) · Neoplasms by Histologic Type (31) · Neoplasms, Glandular and Epithelial (28) · Carcinoma (25) · Respiratory Tract Diseases (18) · Adenocarcinoma (17) · Digestive System Diseases (17) · Digestive System Neoplasms (17) · Lung Diseases (17) · Gastrointestinal Diseases (16)
lenvatinib (8) · pembrolizumab (6) · trametinib (6) · Sorafenib (5) · dabrafenib (5) · Everolimus (4) · Doxorubicin (3) · Iodine-131 (3) · Thyrotropin Alfa (3) · anlotinib (3) · apatinib (3) · vandetanib (3) · 130-nm albumin-bound paclitaxel (2) · Biopsy, Large-Core Needle (2) · Capecitabine (2)
Fudan University (7) · Memorial Sloan Kettering Cancer Center (7) · Dana-Farber Cancer Institute (4) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (4) · Eisai Inc. (3) · M.D. Anderson Cancer Center (3) · Amgen (2) · Genzyme, a Sanofi Company (2) · National Cancer Center, Korea (2) · National University Hospital, Singapore (2) · Peking Union Medical College Hospital (2) · TransThera Sciences (Nanjing), Inc. (2) · University of Michigan Rogel Cancer Center (2) · Washington University School of Medicine (2) · West China Hospital (2)
United States (50) · China (19) · France (13) · Italy (7) · South Korea (7) · Spain (7) · United Kingdom (7) · Australia (6) · Canada (6) · Belgium (5) · Netherlands (4) · Denmark (3) · Germany (3) · Poland (3) · Russia (3)
Eric Sherman, MD (3) · Joanna Klubo-Gwiezdzinska, M.D. (2) · Kartik Seghal, MD (2) · Alan Ho, MD, PhD (1) · Alan L Ho, MD, PhD (1) · Alexander Pearson (1) · Andrew M Scott, MD, FRACP (1) · Angeliki M Stamatouli, MD (1) · Annie M Sawka, MD, PhD (1) · Brendan Knapp, M.D. (1) · Christine H. Chung, M.D. (1) · David P Goldstein, MD (1) · Francis P Worden, MD (1)
PMID 16384850, PMID 18596272, PMID 19158200, PMID 19773371, PMID 20484486, PMID 20739388, PMID 22479375, PMID 22753906, PMID 23009127, PMID 23990665, PMID 25086465, PMID 25581596, PMID 26041482, PMID 26088605, PMID 26163763, PMID 26195199, PMID 27240885, PMID 28299283, PMID 30053006, PMID 30069758, PMID 30261427, PMID 30638399, PMID 30943124, PMID 31682550, PMID 31931920, PMID 31980466, PMID 32359091, PMID 32919526, PMID 33429738, PMID 33619600, PMID 33750196, PMID 33769497, PMID 33836153, PMID 34293201, PMID 34610756, PMID 34664662, PMID 34965951, PMID 34990208, PMID 34998048, PMID 35114169, PMID 35361487, PMID 35588692, PMID 35680043, PMID 35777186, PMID 35835611, PMID 36464853, PMID 36748723, PMID 38478516, PMID 38954633, PMID 39264376
2014 (2), 2016 (2), 2015 (1), 2025 (1), R01CA220681 (1), R21DK122310 (1)